Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2024-12-26 Capital/Financing Update
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the SEC, which is used for registering securities for resale or offering by an already public company. It includes detailed information about the securities being registered, the selling shareholder, and the terms of the offering. This is a capital markets filing related to fundraising and securities registration, not a financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains the full registration statement text, not just an announcement or a brief notice. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-12-26 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a press release about entering a binding term sheet, which is a typical content for a 6-K filing. The document is relatively short (2354 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed presentation. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2024-12-23 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, NeuroSense Therapeutics Ltd., submitted to the SEC. It references a press release dated December 18, 2024, which provides a business update and third quarter 2024 financial results. The document itself is short (2411 characters) and primarily furnishes the press release as Exhibit 99.1. It incorporates the Q3 2024 financial results by reference but does not contain the full financial statements or detailed analysis itself. According to the 'MENU VS MEAL' rule, this is an announcement of a report (the press release) rather than the full report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such filings that do not contain full financial reports but provide regulatory updates or announcements.
2024-12-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content focuses on Nasdaq listing compliance issues, equity transactions, and capital raising activities to regain compliance with Nasdaq's minimum stockholders' equity rule. It details private placements, warrant issuances, and capital on demand sales agreements, all related to financing and capital structure changes. There are no comprehensive financial statements or detailed financial performance analysis typical of annual or interim reports. The document is not a simple announcement of a report but a substantive regulatory filing reporting capital and financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9074 characters) supports it being a full report rather than a brief announcement or certification.
2024-12-17 English
Regulatory Filings 2024
Regulatory Filings
2024-12-13 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed on Form 424B3, which is a type of registration statement used for the resale of securities by selling shareholders. It details the offering of ordinary shares and warrants by a selling shareholder, including the number of shares, exercise prices, and the terms of resale. The document includes sections typical of a prospectus such as risk factors, use of proceeds, plan of distribution, and legal matters. It is not a financial report, earnings release, or management discussion, but rather a capital markets document related to securities offering and resale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus, not just an announcement of a report.
2024-12-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.